Stada Will Continue To Invest To Drive Growth
CEO Peter Goldschmidt Is Seeking Both Organic And Inorganic Expansion
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.
